Page last updated: 2024-08-24

gemcitabine and Cancer of Prostate

gemcitabine has been researched along with Cancer of Prostate in 52 studies

Research

Studies (52)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (7.69)	18.2507
2000's	31 (59.62)	29.6817
2010's	16 (30.77)	24.3611
2020's	1 (1.92)	2.80

Authors

Authors	Studies
Anderes, K; Blasina, A; Chen, E; Chen, P; Deng, Y; Grant, S; Hu, Q; Johnson, MD; Kania, RS; Kornmann, J; Lundgren, K; Ninkovic, S; Peng, Z; Register, J; Rogers, C; Teng, M; Zhu, J	1
Dimas, K; Eleutheriades, A; Foscolos, GB; Georgakopoulou, S; Khan, H; Kourafalos, VN; Mantelas, A; Mirjolet, JF; Moutsos, VI; Papanastasiou, I; Pondiki, S; Prassa, M; Riganas, S; Serin, G; Theodoropoulou, M; Tsotinis, A; Vamvakides, A; Zaniou, A	1
Búzová, D; Červený, J; Culig, Z; Drápela, S; Fedr, R; Hampl, A; Khirsariya, P; Krejčí, L; Paruch, K; Puhr, M; Souček, K; Suchánková, T; van Weerden, WM; Watson, WR	1
Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H	1
Abel, G; Barthelmes, J; Dueregger, A; Guggenberger, F; Haunschild, J; Intelmann, D; Klocker, H; Ramoner, R; Sampson, N; Schuh, M; Stecher, G	1
Ahn, H; Ahn, JH; Choi, MK; Hong, BS; Hong, JH; Hong, SW; Jeong, IG; Kim, Y; Lee, JL; Lee, KH; Song, C	1
Guo, Z; Li, X; Su, B; Xie, F; Zhang, M; Zhang, X; Zhou, L	1
Chu, GC; Chung, LW; Li, Q; Shi, C; Wu, JB; Xu, Q; Yu, JS; Zhang, Y; Zhau, HE	1
Arai, Y; Ito, A; Kaiho, Y; Kamiyama, Y; Kawamorita, N; Mitsuzuka, K; Nakagawa, H; Watanabe, M; Yamada, S	1
Aljarah, AK; Han, B; Ide, H; Inoue, S; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Patterson, JD; Shareef, HK; Zheng, Y	1
Ceballos, J; García-Foncillas, J; Pérez-Gracia, JL; Santisteban, M; Vivas, I	1
Brooks, KJ; Coleman, EJ; Vitetta, ES	1
Debus, J; Heilmann, M; Hennink, WE; Huber, PE; Kiessling, F; Kühnlein, R; Lammers, T; Peschke, P; Storm, G; Subr, V; Ulbrich, K	1
Esser, N; Graeser, R; Jantscheff, P; Kluth, J; Massing, U; Unger, C; Ziroli, V	1
Batra, SK; Davis, JS; Davis, TL; Hauke, R; Lin, FF; Lin, MF; Schutte, R; Zelivianski, S; Zhang, L	1
Esser, N; Graeser, R; Jantscheff, P; Kluth, J; Massing, U; Sukolinskaya, A; Taylor, LA; Unger, C; Ziroli, V	1
Halldén, G	1
Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L	1
Aoki, K; Ikeda, T; Kikugawa, T; Miura, N; Nishida, T; Ochi, T; Ozawa, A; Sasaki, T; Shimamoto, K; Tanji, N; Yanagihara, Y; Yokoyama, M	1
Ito, T; Kawashima, H; Nakatani, T; Omachi, T; Tamada, S	1
Dreicer, R; Elson, P; Garcia, JA; Hutson, TE; Shepard, D	1
Hayashi, T; Kakuta, Y; Nakai, Y; Nakao, A; Nakayama, M; Nonomura, N; Okumi, M; Takayama, H	1
Brümmer, F; Gebhard, MM; Gross, W; Herr, I; Kallifatidis, G; Klöppel, A; Liu, L; Ottinger, S; Rausch, V	1
Ben-Josef, E; Lawrence, TS	1
Chen, Y; Kong, D; Liu, R; Wang, G; Xu, Y; Yang, K; Zhang, Z; Zhao, W	1
Culine, S	1
Delpassand, ES; Logothetis, CJ; Millikan, RE; Pagliaro, LC; Tu, SM; Williams, D	1
Chen, YR; Li, H; Lu, YP; Sun, M; Wang, ZP; Wei, Q; Yang, YR; Yue, ZJ	1
Freiha, F; Morgan, K; Srinivas, S	1
Chen, Y; Li, H; Lu, Y; Sun, M; Wang, Z; Wei, Q; Yang, Y; Yue, Z	1
Han, H; Liu, ZW; Qin, ZK; Wu, ZG; Yang, GW; Zhou, FJ; Zhou, NN	1
Akada, M; Crnogorac-Jurcevic, T; Lattimore, S; Lemoine, NR; Lopes, R; Mahon, P; Matsuno, S; Sunamura, M	1
Friedrich, C; Krege, S; Pientka, L; Rübben, H	1
Dieringer, P; Jonasch, E; Mathew, P; Pagliaro, LC; Rodney, A; Tannir, N	1
Budman, DR; Calabro, A	1
Li, M; Rayburn, ER; Wang, H; Wang, W; Zhang, R; Zhang, Z	1
Aoki, H; Arai, Y; Endoh, M; Ishidoya, S; Ito, A; Shimazui, T	1
Kasman, L; Lu, P; Voelkel-Johnson, C	1
Altieri, V; Autorino, R; Benincasa, G; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M; Morelli, E; Napodano, G; Russo, A	1
Habuchi, T; Inoue, T; Kakinuma, H; Kanzaki, M; Kumazawa, T; Narita, S; Saito, M; Tsuchiya, N; Yuasa, T	1
Kibble, A	1
Hashimoto, Y; Kato, T; Kohri, K; Okada, S; Takahashi, S; Tozawa, K	1
Altmann, A; Bellemann, ME; Blatter, J; Haberkorn, U; Kahn, B; Morr, I; Oberdorfer, F; van Kaick, G	1
Bartsch, G; Böck, G; Cronauer, MV; Culig, Z; Geisen, FH; Hobisch, A; Klocker, H; Konwalinka, G; Radmayr, C; Reissigl, A; Schirmer, M; Talasz, H	1
Altmann, A; Bellemann, ME; Blatter, J; Brix, G; Doll, J; Gerlach, L; Haberkorn, U; Morr, I; Oberdorfer, F; van Kaick, G	1
Budman, DR; Calabro, A; Kreis, W	1
Akaza, H; Hattori, K	1
Bauer, J; Bernhard, J; Borner, M; Fey, MF; Hanselmann, S; Hering, F; Hürny, C; Jacky, E; Maibach, R; Morant, R; Thürlimann, B; Trinkler, F; Zulian, G	1
Cass, CE; Clarke, ML; Gourdeau, H; Jolivet, J; Lafrenière, RG; Lee, N; Mackey, JR; Mowles, D; Ouellet, F; Richard, A; Selner, M; Young, JD	1
Bagrova, SG	1
Vogelzang, NJ	1
Assmann, G; Eckel, F; Lersch, C; Schulte-Frohlinde, E	1

Reviews

5 review(s) available for gemcitabine and Cancer of Prostate

Article	Year
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2009, Volume: 14 Suppl 1 Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication	2009
[Gemcitabine and urogenital tumors]. Bulletin du cancer, 2002, Volume: 89 Spec No Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Germinoma; Hematologic Diseases; Humans; Kidney Neoplasms; Male; Methotrexate; Organoplatinum Compounds; Patient Selection; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms; Vinblastine	2002
[Geriatric urology -- tumour diseases]. Aktuelle Urologie, 2006, Volume: 37, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Male; Middle Aged; Patient Care Team; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms; Urogenital Neoplasms	2006
[New combination chemotherapy in urological cancers]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine	2000
Future directions for gemcitabine in the treatment of genitourinary cancer. Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 3 Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Forecasting; Gemcitabine; Humans; Kidney Neoplasms; Male; Morbidity; Prostatic Neoplasms; Survival Analysis; Testicular Neoplasms; Treatment Outcome; United States; Urinary Bladder Neoplasms; Urogenital Neoplasms	2002

Trials

10 trial(s) available for gemcitabine and Cancer of Prostate

Article	Year
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic oncology, 2018, Volume: 148, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome	2018
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. British journal of cancer, 2014, May-13, Volume: 110, Issue:10 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome	2014
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids	2010
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial. Cancer, 2011, Feb-15, Volume: 117, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids	2011
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer, 2003, Jun-15, Volume: 97, Issue:12 Topics: Aged; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Strontium; Strontium Radioisotopes; Testosterone	2003
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer, 2006, May-15, Volume: 106, Issue:10 Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Probability; Prognosis; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome	2006
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology, 2007, Volume: 69, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Pain Measurement; Palliative Care; Prednisone; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid	2007
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Hormones; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pain Measurement; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate	2000
[Results of phase II clinical trial of cycloplatam in refractory solid tumors]. Voprosy onkologii, 2001, Volume: 47, Issue:6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Pleural Neoplasms; Pleurisy; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine	2001
Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study. Cancer investigation, 2002, Volume: 20, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostatic Neoplasms	2002

Other Studies

37 other study(ies) available for gemcitabine and Cancer of Prostate

Article	Year
Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors. Journal of medicinal chemistry, 2007, Nov-01, Volume: 50, Issue:22 Topics: Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Indazoles; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Structure-Activity Relationship	2007
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain. Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22 Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Female; Humans; Male; Mice; Mice, SCID; Molecular Structure; Neuralgia; Ovarian Neoplasms; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Protein Binding; Receptors, sigma; Structure-Activity Relationship; Tumor Cells, Cultured	2012
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular oncology, 2020, Volume: 14, Issue:10 Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, SCID; Mitosis; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyrimidines; S Phase; Xenograft Model Antitumor Assays	2020
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2013, Nov-15, Volume: 20, Issue:14 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Line; Cell Proliferation; Cimicifuga; Deoxycytidine; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Humans; Male; Nucleosides; Phytotherapy; Plant Extracts; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Saponins; Thymidine; Vidarabine	2013
Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine. Oncology reports, 2015, Volume: 33, Issue:3 Topics: Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGN Proteins; Humans; Male; MAP Kinase Signaling System; Neoplasm Invasiveness; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Sequence Analysis, DNA; Trans-Activators	2015
Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor. Biomaterials, 2015, Volume: 67 Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Deoxycytidine; Diagnostic Imaging; Drug Delivery Systems; Fluorescent Dyes; Gemcitabine; HEK293 Cells; Humans; Hypoxia; Male; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Organic Anion Transporters; Prostatic Neoplasms; Spectroscopy, Near-Infrared; Xenograft Model Antitumor Assays	2015
Chemotherapy with Gemcitabine and Cisplatin for Advanced Ductal Adenocarcinoma of the Prostate: Clinical Courses of Two Patients. The Tohoku journal of experimental medicine, 2015, Volume: 237, Issue:4 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Prostatic Neoplasms	2015
Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine. The Prostate, 2016, Volume: 76, Issue:8 Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Interactions; ets-Domain Protein Elk-1; Gemcitabine; Gene Silencing; Humans; Indoles; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Mas; Receptors, Androgen	2016
Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:6 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed	2008
The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines. International journal of cancer, 2008, Nov-15, Volume: 123, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Prostatic Neoplasms; Transplantation, Heterologous	2008
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. British journal of cancer, 2008, Sep-16, Volume: 99, Issue:6 Topics: Acrylamides; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Gadolinium; Gemcitabine; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Nanomedicine; Prostatic Neoplasms; Radiation Tolerance; Rats; Ribonucleotide Reductases; Tissue Distribution	2008
Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. The Prostate, 2009, Aug-01, Volume: 69, Issue:11 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Prostatic Neoplasms; Splenic Neoplasms; Transplantation, Heterologous	2009
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment. Cancer letters, 2009, Nov-18, Volume: 285, Issue:1 Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Time Factors; Tyrphostins	2009
Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clinical & experimental metastasis, 2009, Volume: 26, Issue:8 Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Capillary Permeability; Cell Line, Tumor; Cells, Cultured; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Liposomes; Luciferases; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Transduction, Genetic; Xenograft Model Antitumor Assays	2009
Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. International journal of clinical oncology, 2010, Volume: 15, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium	2010
[Primary urothelial carcinoma with sarcomatous transformation of the prostate]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2010, Volume: 101, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sarcoma; Treatment Outcome; Urethral Neoplasms	2010
[A case of leiomyosarcoma of prostate: multimodality therapy suppressed disease progression for long term]. Hinyokika kiyo. Acta urologica Japonica, 2010, Volume: 56, Issue:9 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Prostatic Neoplasms; Taxoids	2010
Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract. International journal of cancer, 2012, Apr-01, Volume: 130, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Crambe Sponge; Deoxycytidine; Endothelial Cells; Female; Fibroblasts; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Prostatic Neoplasms	2012
Radiotherapy: the importance of local control in pancreatic cancer. Nature reviews. Clinical oncology, 2011, Nov-29, Volume: 9, Issue:1 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Smad4 Protein	2011
Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer. Molecular carcinogenesis, 2013, Volume: 52, Issue:3 Topics: Animals; Apoptosis; Bystander Effect; Connexin 43; Dendrimers; Deoxycytidine; Ganciclovir; Gemcitabine; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Lipids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Polyamines; Promoter Regions, Genetic; Prostatic Neoplasms; Simplexvirus; Thymidine Kinase; Transfection; Xenograft Model Antitumor Assays	2013
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2004, Volume: 24, Issue:9 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms	2004
Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. Urology, 2004, Volume: 64, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Incidental Findings; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Orchiectomy; Positron-Emission Tomography; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Testicular Neoplasms; Transurethral Resection of Prostate; Ultrasonography; Urinary Bladder Neoplasms; Urinary Diversion	2004
[The synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3]. Zhonghua nan ke xue = National journal of andrology, 2004, Volume: 10, Issue:9 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms	2004
[Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:12 Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Ribonucleotide Reductases; Survival Rate	2004
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8 Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger	2005
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology, 2006, Volume: 70, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid	2006
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. The Prostate, 2006, Nov-01, Volume: 66, Issue:15 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Oligonucleotides; Phosphatidylethanolamines; Prostatic Neoplasms; RNA, Messenger; Taxoids; Toll-Like Receptor 9	2006
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. International journal of urology : official journal of the Japanese Urological Association, 2006, Volume: 13, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prostatic Neoplasms; Taxoids	2006
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer gene therapy, 2007, Volume: 14, Issue:3 Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Deoxycytidine; Depsipeptides; Doxorubicin; Gemcitabine; Genetic Therapy; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Prostate; Prostatic Neoplasms; Pyridines; TNF-Related Apoptosis-Inducing Ligand	2007
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncology reports, 2007, Volume: 17, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Docetaxel; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays	2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome	2007
Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine. International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:12 Topics: Adenocarcinoma; Antineoplastic Agents; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male; Middle Aged; Prostatic Neoplasms	2007
Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1994, Volume: 35, Issue:11 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxyglucose; Fluorodeoxyglucose F18; Gemcitabine; In Vitro Techniques; Male; Prostatic Neoplasms; Rats; Tomography, Emission-Computed; Tumor Cells, Cultured	1994
Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. The Prostate, 1996, Volume: 28, Issue:3 Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Division; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cells; Humans; Male; Prostatic Neoplasms; Tumor Cells, Cultured	1996
PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1997, Volume: 38, Issue:8 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; Deoxyglucose; DNA, Neoplasm; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Male; Neoplasm Transplantation; Prostatic Neoplasms; Radiopharmaceuticals; Rats; Ribonucleotide Reductases; Thymidine; Tomography, Emission-Computed; Tritium; Tumor Cells, Cultured	1997
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anti-cancer drugs, 1998, Volume: 9, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine	1998
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer research, 2001, Oct-01, Volume: 61, Issue:19 Topics: Amino Acid Sequence; Antineoplastic Agents; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Male; Membrane Proteins; Molecular Sequence Data; Nucleoside Transport Proteins; Phosphorylation; Prostatic Neoplasms; Sequence Homology, Amino Acid; Sodium; Stereoisomerism; Tritium; Tumor Cells, Cultured; Uridine	2001